Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

被引：9

作者：

Lonial, Sagar

Dimopoulos, Meletios A.

Weisel, Katja

White, Darrell

Moreau, Philippe

Mateos, Maria-Victoria

San-Miguel, Jesus

Anderson, Kenneth Carl

Shpilberg, Ofer

Grosicki, Sebastian

Spicka, Ivan

Walter-Croneck, Adam

Magen, Hila

Belch, Andrew

Reece, Donna Ellen

Beksac, Meral

Shelat, Suresh

Sy, Oumar

Singhal, Anil K.

Richardson, Paul G.

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Univ Tubingen, Tubingen, Germany

[4] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Univ Hosp, Nantes, France

[7] Univ Hosp Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

[8] Clin Univ Navarra, Ctr Invest Med Aplicada, IDISNA, CIBERONC, Pamplona, Spain

[9] Dana Farber Canc Inst, Boston, MA USA

[10] Assuta Med Ctr, Inst Haematol, Tel Aviv, Israel

[11] Med Univ Silesia, Katowice, Poland

[12] Charles Univ Prague, Prague, Czech Republic

[13] Gen Teaching Hosp, Prague, Czech Republic

[14] Med Univ Lublin, Lublin, Poland

[15] Sheba Med Ctr Hosp Tel HaShomer, Ramat Gan, Israel

[16] Cross Canc Inst, Edmonton, AB, Canada

[17] Univ Alberta, Edmonton, AB, Canada

[18] Princess Margaret Hosp, Toronto, ON, Canada

[19] Ankara Univ, Ankara, Turkey

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] AbbVie, Redwood City, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.8040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8040

引用

页数：1